Free US stock valuation models and price target projections from professional analysts covering Wall Street expectations and analyst consensus. We help you understand fair value estimates and potential upside or downside scenarios for any stock you are considering. Our platform provides multiple valuation methods, comparable company analysis, and discounted cash flow models. Make smarter valuation decisions with our comprehensive tools and expert projections based on Wall Street research.
Intellia Therapeutics Inc. (NTLA), a clinical-stage biotech firm focused on CRISPR-based gene editing therapies, is trading at $13.55 as of 2026-04-07, marking a 1.88% gain on the day. This analysis covers key near-term technical levels, prevailing sector context, and potential price scenarios for the stock in the coming weeks, with no investment recommendations included. Key takeaways include well-defined near-term support and resistance levels that have held across multiple recent tests, mixed
Is Intellia Therapeutics (NTLA) Stock a Value Play | Price at $13.55, Up 1.88% - Investment Signal Network
NTLA - Stock Analysis
3348 Comments
967 Likes
1
Kyraa
Active Contributor
2 hours ago
This feels like something I forgot.
π 75
Reply
2
Tajmere
Returning User
5 hours ago
That deserves a meme. π
π 209
Reply
3
Cylo
Senior Contributor
1 day ago
A slight dip in the indices may be a short-term buying opportunity.
π 85
Reply
4
Annalyse
Influential Reader
1 day ago
That deserves a slow-motion replay. π¬
π 244
Reply
5
Kyrone
Active Reader
2 days ago
Too late now⦠sigh.
π 125
Reply
Disclaimer: Not investment advice. For informational purposes only. Past performance does not guarantee future results. Trading involves substantial risk of loss.